NASDAQ:PRLD Prelude Therapeutics (PRLD) Stock Price, News & Analysis $0.83 +0.05 (+6.21%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.90 +0.07 (+8.66%) As of 08/1/2025 06:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Prelude Therapeutics Stock (NASDAQ:PRLD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Prelude Therapeutics alerts:Sign Up Key Stats Today's Range$0.77▼$0.8750-Day Range$0.78▼$1.1852-Week Range$0.61▼$6.80Volume74,562 shsAverage Volume123,091 shsMarket Capitalization$46.77 millionP/E RatioN/ADividend YieldN/APrice Target$4.50Consensus RatingBuy Company Overview Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware. Read More Prelude Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScorePRLD MarketRank™: Prelude Therapeutics scored higher than 65% of companies evaluated by MarketBeat, and ranked 351st out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingPrelude Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePrelude Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Prelude Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Earnings GrowthEarnings for Prelude Therapeutics are expected to remain at ($1.81) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Prelude Therapeutics is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Prelude Therapeutics is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrelude Therapeutics has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Prelude Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.14% of the float of Prelude Therapeutics has been sold short.Short Interest Ratio / Days to CoverPrelude Therapeutics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Prelude Therapeutics has recently decreased by 4.56%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPrelude Therapeutics does not currently pay a dividend.Dividend GrowthPrelude Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.14% of the float of Prelude Therapeutics has been sold short.Short Interest Ratio / Days to CoverPrelude Therapeutics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Prelude Therapeutics has recently decreased by 4.56%, indicating that investor sentiment is improving. News and Social Media2.0 / 5News SentimentN/A News SentimentPrelude Therapeutics has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Prelude Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders63.90% of the stock of Prelude Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions79.72% of the stock of Prelude Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Prelude Therapeutics' insider trading history. Receive PRLD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prelude Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PRLD Stock News HeadlinesPrelude Therapeutics Incorporated (PRLD) - Yahoo FinanceJune 25, 2025 | finance.yahoo.comPrelude Therapeutics Incorporated (PRLD) - Yahoo FinanceJune 25, 2025 | finance.yahoo.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.August 2 at 2:00 AM | Porter & Company (Ad)Prelude Therapeutics to Present at Major Healthcare Conferences in June 2025June 3, 2025 | msn.comPrelude Therapeutics to Participate in Upcoming Healthcare ConferencesJune 2, 2025 | globenewswire.comPrelude Therapeutics’ SWOT analysis: clinical progress buoys stock amid challengesMay 28, 2025 | investing.comPrelude Therapeutics Reports Q1 2025 Financial Results and Progress on Clinical ProgramsMay 10, 2025 | msn.comPrelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 6, 2025 | globenewswire.comSee More Headlines PRLD Stock Analysis - Frequently Asked Questions How have PRLD shares performed this year? Prelude Therapeutics' stock was trading at $1.2750 on January 1st, 2025. Since then, PRLD shares have decreased by 35.0% and is now trading at $0.8283. How were Prelude Therapeutics' earnings last quarter? Prelude Therapeutics Incorporated (NASDAQ:PRLD) issued its quarterly earnings results on Tuesday, May, 6th. The company reported ($0.42) EPS for the quarter, beating analysts' consensus estimates of ($0.47) by $0.05. When did Prelude Therapeutics IPO? Prelude Therapeutics (PRLD) raised $149 million in an initial public offering on Friday, September 25th 2020. The company issued 8,300,000 shares at $17.00-$19.00 per share. Morgan Stanley, Goldman Sachs and BofA Securities served as the underwriters for the IPO. Who are Prelude Therapeutics' major shareholders? Top institutional shareholders of Prelude Therapeutics include Y Intercept Hong Kong Ltd (0.08%). Insiders that own company stock include Orbimed Advisors Llc, Krishna Vaddi, Andrew Combs and Laurent Chardonnet. View institutional ownership trends. How do I buy shares of Prelude Therapeutics? Shares of PRLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Prelude Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Prelude Therapeutics investors own include Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Visa (V) and Advanced Micro Devices (AMD). Company Calendar Last Earnings5/06/2025Today8/02/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PRLD CIK1678660 Webwww.preludetx.com Phone302-467-1280FaxN/AEmployees120Year FoundedN/APrice Target and Rating Average Price Target for Prelude Therapeutics$4.50 High Price Target$5.00 Low Price Target$4.00 Potential Upside/Downside+443.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($1.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$127.17 million Net MarginsN/A Pretax Margin-1,826.10% Return on Equity-89.18% Return on Assets-69.26% Debt Debt-to-Equity RatioN/A Current Ratio5.18 Quick Ratio5.18 Sales & Book Value Annual Sales$7 million Price / Sales6.68 Cash FlowN/A Price / Cash FlowN/A Book Value$2.39 per share Price / Book0.35Miscellaneous Outstanding Shares56,460,000Free Float20,382,000Market Cap$46.77 million OptionableOptionable Beta1.22 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:PRLD) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prelude Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Prelude Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.